Life Technologies Corporation has announced the creation of the Genomic Cancer Care Alliance in the US to improve cancer treatments through the analysis of genomic information.

Founding partners include Fox Chase Cancer Center, Scripps Genomic Medicine and the Translational Genomics Research Institute (TGen).

The Alliance will launch a pilot study aimed at determining whether whole-genome sequencing can better guide treatment decisions across difficult-to-treat cancers.

US Oncology Inc will serve as the contract research and site management organisation for the study.

The study builds on a research trial announced earlier this year by Life Technologies, TGen and US Oncology to sequence the genomes of 14 patients diagnosed with triple negative breast cancer whose tumours have progressed despite undergoing other therapies.

This new alliance will be the first to evaluate the use of whole-genome sequencing information in guiding treatment decisions across a wide range of cancer types.

The Alliance plans to begin enrolling patients later this year for trials that are expected to focus on advanced cancer patients who have failed initial rounds of therapy.